Format

Send to

Choose Destination
Neurology. 2004 Aug 24;63(4):746-8.

Improvement of motor function in early Parkinson disease by safinamide.

Author information

1
Department of Neuroscience and IRCCS Neuromed Pozzilli (IS), Disorders Centre, Department of Neuroscience, Universita' G. D'Annunzio, Chieti-Pescara, Pescara, Italy. ruggero.fariello@newron.com

Abstract

A median safinamide (SAF) dose of 70 mg/day (range 40 to 90 mg/day) increased the percentage of parkinsonian patients improving their motor scores by > or =30% from baseline (responders) after 3 months from 21.4% (placebo) to 37.5% (p < 0.05, calculated by logistic regression analysis). In a subgroup of 101 patients under stable treatment with a single dopamine agonist, addition of SAF magnified the response (47.1% responders, mean 4.7-point motor score decrease; p > or = 0.05). These results suggest that doses of SAF exerting ion channel block and glutamate release inhibition add to its symptomatic effect and warrant exploration of higher doses.

PMID:
15326260
[Indexed for MEDLINE]

Publication types, MeSH terms, Substances

Publication types

MeSH terms

Substances

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center